

1 *Communication*

2 **Strong correlations between the binding antibodies against wild type and**
3 **neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-**
4 **CoV-2 in individuals following booster (third dose) vaccination**

5 Nungruthai Suntronwong^{1#}, Suvichada Assawakosri^{1#}, Sitthichai Kanokudom¹, Ritthideach
6 Yorsaeng¹, Chompoonut Auphimai¹, Thanunrat Thongmee¹, Preeyaporn Vichaiwattana¹,
7 Thaneeya Duangchinda², Warangkana Chantima^{3,4}, Pattarakul Pakchotanon², Jira Chansaenroj¹,
8 Pornjarim Nilyanimit¹, Donchida Srimuan¹, Thaksaporn Thatsanatorn¹, Natthinee Sudhinaraset¹,
9 Nasamon Wanlapakorn¹, Juthathip Mongkolsapaya^{5,6}, Yong Poovorawan^{1,7*}

10 ¹Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok
11 10330, Thailand

12 ² Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
13 Engineering and Biotechnology (BIOTEC), National Science and Development Agency, NSTDA,
14 Pathum Thani 12120, Thailand

15 ³ Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital, Mahidol
16 University, Bangkok 10700, Thailand

17 ⁴ Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj
18 Hospital, Mahidol University, Bangkok 10700, Thailand

19 ⁵ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
20 Oxford, OX3 7BN, UK

21 ⁶ Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford,
22 UK

23 ⁷ The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand

24 # Equally contributed

25 *Correspondence: email: yong.p@chula.ac.th; Tel.: +662-256-4929

26

27 **Abstract:** This study examined the neutralizing activity and receptor binding domain (RBD)
28 antibody levels against wild-type and omicron BA.1 and BA.2 variants in individuals who
29 received three doses of COVID-19 vaccination. The relationship between the SARS-CoV-2 RBD
30 antibody against wild-type and live virus neutralizing antibody titers against omicron BA.1 and
31 BA.2 variants was examined. In total, 310 sera samples from individuals after booster
32 vaccination (third dose) vaccination were tested for specific IgG wild-type SARS-CoV-2 RBD
33 and the omicron BA.1 surrogate virus neutralization test (sVNT). The live virus neutralization
34 assay against omicron BA.1 and BA.2 was performed using the foci-reduction neutralization test
35 (FRNT50). The anti-RBD IgG strongly correlated with FRNT50 titers against BA.1 and BA.2.
36 Non-linear regression showed that anti-RBD IgG with ≥ 148 BAU/mL and ≥ 138 BAU/mL were
37 related to detectable FRNT50 titers ($\geq 1:20$) against BA.1 and BA.2, respectively. A moderate
38 correlation was observed between the sVNT and FRNT50 titers. At detectable FRNT50 titers
39 ($\geq 1:20$), the predicted sVNT for BA.1 and BA.2 were $\geq 10.57\%$ and $\geq 11.52\%$, respectively. The
40 study identified anti-RBD IgG and sVNT levels that predict detectable neutralizing antibodies
41 against omicron variants. Assessment and monitoring of protective immunity support vaccine
42 policies and will help identify optimal timing for booster vaccination.

43 **Keywords:** COVID-19; SARS-CoV-2; neutralization; omicron; antibody; correlation

44

45 **1. Introduction**

46 Detection of neutralizing antibodies helps to predict humoral immunity protection and
47 monitor waning immunity and vaccine immunogenicity. Numerous studies have shown that a
48 high level of neutralizing antibodies is correlated with SARS-CoV-2 protection and reduces the
49 severity of the disease [1-3]. However, the current gold standard neutralization assay (live virus

50 neutralization assay) has been limited to widespread use due to the need for specially trained
51 personnel to handle the live SARS-CoV-2 virus and the need to work in a biosafety level 3
52 laboratory (BSL3) containment facility.

53 Although several commercial kits were available to detect the SARS-CoV-2 antibody and
54 are currently used in hospital and clinical laboratories, the antigens tested derived from the
55 ancestral strain because tests were developed before the SARS-CoV-2 variants emerged [4].
56 Furthermore, surrogate virus neutralization (sVNT) is widely performed to determine the ability
57 to neutralize antibodies to block the interaction between the receptor binding domain (RBD) and
58 human ACE2 receptors [5]. Several studies have shown that the commercial binding antibody
59 assay and sVNT are well correlated with the gold standard results of the neutralization method
60 against the ancestral strain [6-8]. Due to the spread of SARS-CoV-2 omicron variants, concerns
61 have been raised as to whether preexisting immunity is sufficient to protect the omicron
62 infection. However, the relationship between the anti-RBD IgG against wild-type and live virus
63 neutralization assay against the omicron has been limited.

64 In this study, we applied non-linear regression analysis to predict the level of anti-RBD
65 IgG and sVNT related to the detectable level of FRNT₅₀ titers against omicron variants,
66 including the BA.1 and BA.2 subvariants, in serum collected from individuals after receiving the
67 COVID-19 booster (third dose) vaccination.

68 **2. Materials and Methods**

69 *2.1 Participants and ethical considerations*

70 Our study recruited 310 sera samples from individuals after receiving the booster (third
71 dose) COVID-19 vaccination from previous studies [9, 10]. There were two primed cohorts for
72 analysis. The first cohort was primed with two doses of AZD1222 and boosted with AZD1222,

73 BNT162b2, 50 µg of mRNA-1273 or 100 µg of mRNA-1273 6 months after the first
74 vaccination. The second cohort was primed with heterologous CoronaVac/ASD1222 and boosted
75 with AZD1222, BNT162b2, and 100 µg mRNA-1273 approximately 4–5 months after the initial
76 vaccination. The enrollment period was between November 2021 and January 2022. Blood
77 samples were collected at day 0 and at days 28 and 90 post-booster. This study was performed
78 following the Declaration of Helsinki and Good Clinical Practice principles. The study protocol
79 was reviewed and approved by the Institutional Review Board of the Faculty of Medicine of
80 Chulalongkorn University (IRB numbers 871/64 and 690/64). All participants signed a written
81 consent before being enrolled.

82 *2.2 Measurement anti-RBD IgG and sVNT*

83 All sera samples were quantitatively measured for wild-type SARS-CoV-2 receptor
84 binding domain (RBD) specific IgG (anti-RBD IgG) using the commercial assay, Abbott SARS-
85 CoV-2 IgG II Quant assay (Abbott Diagnostics, Abbott Park, IL). Anti-RBD IgG was reported as
86 a binding antibody unit (BAU/mL). The surrogate virus neutralization assay (sVNT) against
87 variants of BA.1 was performed using a cPass™ SAR-CoV-2 neutralizing antibody detection
88 kit (GenScript Biotech, Piscataway, NJ) as previously described [9, 10].

89 *2.3 Foci reduction neutralization test (FRNT50)*

90 For the live virus neutralization test, the foci reduction neutralization test (FRNT50) was
91 performed using the live SARS-CoV-2 virus, which included the omicron BA.1 (GISAID
92 accession number: EPI_ISL_8547017), BA.2 (accession number: EPI_ISL_11698090)
93 subvariants as previously described [9, 10]. The FRNT50 titer ≥ 20 was considered a detectable

94 level of neutralizing antibody if the neutralizing antibody titer was undetected (FRNT50 titer <
95 20), the FRNT50 was set as 10.

96 *2.4 Statistical analysis*

97 For statistical analysis, the predicted values of anti-RBD IgG and sVNT at FRNT50 titers
98 ≥ 20 and ≥ 40 were determined using non-linear regression analysis and performed on the log₁₀
99 transformed data. The Spearman's rank correlation between anti-RBD IgG, sVNT, and FRNT50
100 titers was determined using SPSS v23.0 (IBM Corp, Armonk, NY). The r-square was calculated
101 according to the non-linear equation using STATA v.17.0 software. A P-value <0.05 was
102 considered statistically significant.

103

104 **3. Results**

105 *3.1 Correlations between anti-RBD IgG to wild-type and FRNT50 titers against omicron*

106 A total of 310 sera samples from individuals receiving different booster vaccination were
107 tested for wild-type anti-RBD IgG and FRNT50 of BA.1 and BA.2 (Table 1). The FRNT50 titer
108 ranged from undetectable (<1:20) to 3552 for BA.1 and undetectable to 3249 for BA.2 as
109 examined on day 0 and on days 28 and 90. The correlation analysis indicated that anti-RBD IgG
110 was strongly correlated with FRNT50 titers against BA.1 (Spearman R: 0.89, $p < 0.001$) and BA.2
111 (Spearman R: 0.86, $p < 0.001$) (S1 Table). Non-linear regression analysis showed the predicted
112 anti-RBD IgG was 148 BAU/mL and 335 BAU/mL when the FRNT50 titers against omicron
113 BA.1 were 20 (1.3 of log₁₀ FRNT50 titers) and 40 (1.6 of log₁₀ F FRNT50 titers), respectively
114 ($r^2 = 0.79$, $P < 0.001$) (Fig 1a). In addition, the predicted anti-RBD IgG was approximately 138
115 BAU/mL and 298 BAU/mL when the FRNT50 titer to omicron BA.2 was 20 and 40,

116 respectively ($r^2=0.73$, $P<0.001$) (Fig 1b). When the cut-off value of 1:20 for the neutralization
117 test was used for BA.1, the anti-RBD IgG cut-off of 148 BAU/mL showed 89.7% sensitivity and
118 81.4% specificity; whereas, for BA.2, the anti-RBD IgG cut-off of 138 BAU/mL showed 86.8%
119 sensitivity and 82.9% specificity.

120

121 *3.2 Correlations between sVNT to omicron and FRNT50 titers against omicron*

122 The relationship between sVNT and FRNT₅₀ titers was determined and a moderate
123 correlation between the sVNT and FRNT₅₀ titers was observed (Spearman's $R=0.77$ and 0.78 for
124 BA.1 and BA.2, $p<0.001$) (S1 Table). Non-linear regression showed that the predicted sVNT
125 was 10.57% and 18.22% and were related to 20 and 40 FRNT₅₀ titers for BA.1 ($r^2=0.59$,
126 $P<0.001$). Although sVNT was 11.52% and 16.21% related to the 20 and 40 FRNT₅₀ titers for
127 BA.2 ($r^2=0.64$, $P<0.001$). When the cut-off level of 1:20 for the neutralization test was used for
128 BA.1, the sVNT of $\geq 10.57\%$ showed 86.4% sensitivity and 73.1% specificity, whereas for BA.2,
129 the sVNT of $\geq 11.52\%$ showed 82.3% sensitivity and 63.2% specificity. The ROC analysis
130 indicated that anti-RBD IgG and sVNT provided good performance in detecting neutralizing
131 antibodies against omicron variants (Supplementary Fig. 1a-d).

132 **4. Discussion**

133 Numerous studies have shown a strong correlation between the levels of antibody binding
134 response, including anti-spike, anti-RBD antibodies, and neutralizing antibody titers against
135 ancestral strain in individuals with previous COVID-19 infection or vaccination [6, 11-14].
136 However, there is evidence that the binding antibody was poorly correlated with neutralizing
137 antibody titers against variants derived from B.1.1.7 and B.1.351 compared to the ancestral strain

138 [7, 15]. In this study, we found that the anti-RBD IgG and sVNT tested by commercial kits
139 correlated well with neutralizing antibody titers against the SARS-CoV-2 omicron variants. In
140 addition, our data predicted anti-RBD IgG and sVNT at a detectable level of neutralizing
141 antibodies against omicron BA.1 and BA.2 (FRNT50 titers ≥ 20). These findings suggest that
142 boosting immunity against vaccine strain (ancestral strain) could induce cross-reactivity against
143 omicron variants.

144 Anti-RBD IgG measured all antibodies targeting receptor binding sites, neutralizing
145 antibodies, and non-neutralizing antibodies. The antigen for anti-RBD IgG detection was
146 designed on the basis of the ancestral strain. Although more than 30 amino acid mutations were
147 detected in the omicron variant spike protein [16], our results showed that the anti-RBD IgG and
148 neutralizing antibody tested by FRNT50 titers against the omicron variant provided a strong
149 correlation, which is consistent with a previous report [17]. In addition, correlations between
150 neutralizing activity against variants of SARS-CoV-2 and RBD-specific binding antibody have
151 been reported in samples with high binding antibody titers [7]. However, our result was
152 inconsistent with a previous study [18], which showed that anti-RBD IgG was not correlated
153 with the surrogate virus neutralization test against omicron variants.

154 In the comparison of omicron subvariants, although omicron BA.1 and BA.2 shared 12
155 amino acid alterations in RBD compared to wild type D614G [19], the predicted anti-RBD IgG
156 showed higher sensitivity and specificity to detect the neutralizing antibody for omicron BA.1
157 than for BA.2. For sVNT, the RBD recombinant protein was designed based on BA.1 omicron
158 variants. As expected, the sensitivity and specificity between sVNT and BA.1 were higher than
159 BA.2.

160 There are several advantages to using anti-RBD IgG and sVNT to determine the antibody
161 response against SARS-CoV-2. First, these methods do not require the live SARS-CoV-2 virus
162 and a biosafety level 3 facility. Second, they do not require specially trained technicians and are
163 suitable for use in hospitals and clinical laboratories. Additionally, these methods are conducted
164 with high-throughput testing that is less time-consuming and takes 1–2 hours to complete.

165 There are some limitations to this study. First, the sample size was relatively small.
166 However, we addressed the performance analysis by using samples with a wide range of
167 antibody concentrations. Second, we did not perform the sVNT against BA.2 due to the
168 commercial recombinant RBD protein in the production process. Furthermore, the exact level of
169 neutralizing antibodies that protect against SARS-CoV-2 infection has not yet been established.

170 In conclusion, the predicted anti-RBD IgG and sVNT levels corresponding to FRNT50 titers
171 ≥ 20 against the omicron variant showed high sensitivity and specificity. This finding
172 underscores that anti-RBD IgG and sVNT for the omicron variants can be used to predict the
173 presence of neutralizing antibodies against omicron BA.1 and BA.2 subvariants.

174

175 **Funding:** This research was funded by the National Research Council of Thailand (NRCT), the
176 Health Systems Research Institute (HSRI), the Center of Excellence in Clinical Virology of
177 Chulalongkorn University, King Chulalongkorn Memorial Hospital, MK Restaurant Group, and
178 the Second Century Fund Fellowship of Chulalongkorn University. Thaneeya Duangchinda was
179 funded by the National Center for Genetic Engineering and Biotechnology, BIOTEC Platform
180 No. P2051613.

181

182 **Institutional Review Board Statement:** This study was performed following the Declaration of
183 Helsinki and Good Clinical Practice principles. The study protocol was reviewed and approved
184 by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB
185 numbers 871/64 and 690/64).

186
187 **Informed Consent Statement:** All participants signed a written consent before being enrolled.
188 The study was conducted according to the Declaration of Helsinki and the principles of the Good
189 Clinical Practice Guidelines (ICH-GCP).

190
191 **Data Availability Statement:** All data are provided in the manuscript and supplementary files.
192 Additional information can be requested from the corresponding author.

193 **Acknowledgments:** We would like to thank Prof. Stephen Kerr from the Research Affairs,
194 Faculty of Medicine, Chulalongkorn University, for the statistical analysis. We would like to
195 thank the staff of the Center of Excellence in Clinical Virology for helping and supporting this
196 project. Written informed consent has been obtained from the patient(s) to publish this paper.

197 **Conflicts of Interest:** “The authors declare no conflict of interest.”

198

199 **References**

- 200 1. Feng, S.; Phillips, D. J.; White, T.; Sayal, H.; Aley, P. K.; Bibi, S.; Dold, C.; Fuskova,
201 M.; Gilbert, S.C.; Hirsch, I.; et al. Correlates of protection against symptomatic and
202 asymptomatic SARS-CoV-2 infection. *Nat. Med.* **2021**, *27*, 2032–2040.
203 <https://doi.org/10.1038/s41591-021-01540-1>.

- 204 2. Gallais, F.; Gantner, P.; Bruel, T.; Velay, A.; Planas, D.; Wendling, M. J.; Bayer, S.;
205 Solis, M.; Laugel, E.; Reix, N.; et al. Evolution of antibody responses up to 13 months
206 after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*. **2021**, *71*, 103561.
207 <https://doi.org/10.1016/j.ebiom.2021.103561>.
- 208 3. Khoury, D. S.; Cromer, D.; Reynaldi, A.; Schlub, T. E.; Wheatley, A. K.; Juno, J. A.;
209 Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are
210 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat.*
211 *Med.* **2021**, *27*, 1205-11. <https://doi.org/10.1038/s41591-021-01377-8>.
- 212 4. Kobayashi, R.; Suzuki, E.; Murai, R.; Tanaka, M.; Fujiya, Y.; Takahashi, S. Performance
213 analysis among multiple fully automated anti-SARS-CoV-2 antibody measurement
214 reagents: a potential indicator for the correlation of protection in the antibody titer. *J*
215 *Infection Chemother.* **2022**, S1341-321X(22)00165-9.
216 <https://doi.org/10.1016/j.jiac.2022.05.016>.
- 217 5. Tan, C. W.; Chia, W. N.; Qin, X.; Liu, P.; Chen, M. I.; Tiu, C.; Hu, Z.; Chen, V.C.;
218 Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus neutralization test based
219 on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nat.*
220 *Biotechnol.* **2020**, *38*, 1073-8. <https://doi.org/10.1038/s41587-020-0631-z>.
- 221 6. Lee, B.; Ko, J. H.; Park, J.; Moon, H. W.; Baek, J. Y.; Jung, S.; Lim, H.Y.; Kim, K.C.;
222 Huh, K.; Cho, S.Y.; et al. Estimating the neutralizing effect and titer correlation of semi-
223 quantitative anti-SARS-CoV-2 Antibody Immunoassays. *Front. Cell. Infect. Microbiol.*
224 **2022**, *12*, 822599. <https://doi.org/10.3389/fcimb.2022.822599>.
- 225 7. Morinaga, Y.; Tani, H.; Terasaki, Y.; Nomura, S.; Kawasuji, H.; Shimada, T.; Igarashi,
226 E.; Saga, Y.; Yoshida, Y.; Yasukochi, R.; et al. Correlation of the commercial anti-

- 227 SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent
228 reduction neutralizing test and possible detection of antibodies to emerging variants.
229 *Microbiol Spectr.* **2021**, *9*, e00560-21. <https://doi.org/10.1128/Spectrum.00560-21>.
- 230 8. Ramos, A.; Cardoso, M. J.; Ribeiro, L.; Guimarães, J. T. Assessing SARS-CoV-2
231 neutralizing antibodies after BNT162b2 vaccination and their correlation with SARS-
232 CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. *Diagnostics.* **2022**, *12*, 205.
233 <https://doi.org/10.3390/diagnostics12010205>.
- 234 9. Assawakosri, S.; Kanokudom, S.; Chansaenroj, J.; Suntronwong, N.; Auphimai, C.;
235 Nilyanimit, P.; Vichaiwattana, P.; Thongmee, T.; Duangchinda, T.; Chantima, W.; et al.
236 Persistence of immunity against omicron BA.1 and BA.2 following homologous and
237 heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222
238 vaccination. *medRxiv.* **2022**, <https://doi.org/10.1101/2022.06.05.22276016>.
- 239 10. Suntronwong, N.; Kanokudom, S.; Auphimai, C.; Assawakosri, S.; Thongmee, T.;
240 Vichaiwattana, P.; Duangchinda, T.; Chantima, W.; Pakchotanon, P.; Chansaenroj, J.; et
241 al. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to
242 omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
243 *medRxiv.* 2022, <https://doi.org/10.1101/2022.04.25.22274294>.
- 244 11. Dolscheid-Pommerich, R.; Bartok, E.; Renn, M.; Kümmerer, B. M.; Schulte, B.;
245 Schmithausen, R. M.; Stoffel-Wagner, B.; Streeck, H.; Saschenbrecker, S.; Steinhagen,
246 K.; et al. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and
247 neutralization activity. *J. Med. Virol.* **2022**, *94*, 388-92.
248 <https://doi.org/10.1002/jmv.27287>.

- 249 12. Guiomar, R.; Santos, A.J.; Melo, A.; Costa, I.; Matos, R.; Rodrigues, A.P.; Kislaya, I.;
250 Silva, A.S.; Roque, C.; Silva, C.; et al. High correlation between binding IgG (anti-
251 RBD/S) and neutralizing antibodies against SARS-CoV-2 six months after vaccination.
252 *medRxiv*. **2021**, <https://doi.org/10.1101/2021.12.10.21267607>.
- 253 13. Rockstroh, A.; Wolf, J.; Fertey, J.; Kalbitz, S.; Schroth, S.; Lübbert, C.; Ulbert, S.; Borte,
254 S. Correlation of humoral immune responses to different SARS-CoV-2 antigens with
255 virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
256 *Emerg. Microbes Infect.* **2021**, *10*, 774-81.
257 <https://doi.org/10.1080/22221751.2021.1913973>.
- 258 14. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D. R.; Bailey, M. J.; Mansour, M.;
259 McMahon, M.; Meade, P.; Mendu, D.R.; Muellers, K.; et al. Robust neutralizing
260 antibodies to SARS-CoV-2 infection persist for months. *Science*. **2020**, *370*, 1227-30.
261 <https://doi.org/10.1126/science.abd7728>.
- 262 15. Poon, R. W.; Lu, L.; Fong, C. H.; Ip, T. C.; Chen, L. L.; Zhang, R. R.; Yip, C.C.; Cheng,
263 V.C.; Chan, K.H.; Yuen, K.Y.; et al. Correlation between commercial anti-RBD IgG titer
264 and neutralization titer against SARS-CoV-2 beta variant. *Diagnostics*. **2021**, *11*(12),
265 2216. <https://doi.org/10.3390/diagnostics11122216>.
- 266 16. Ou, J.; Lan, W.; Wu, X.; Zhao, T.; Duan, B.; Yang, P.; Ren, Y.; Quan, L.; Zhao, W.;
267 Seto, D.; et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies
268 multiple inter-variant recombination events. *Signal Transduct. Target Ther.* **2022**, *7*, 1-9.
269 <https://doi.org/10.1038/s41392-022-00992-2>.
- 270 17. Medigeshi, G. R.; Batra, G.; Murugesan, D. R.; Thiruvengadam, R.; Chattopadhyay, S.;
271 Das, B.; Gosain, M.; Ayushi; Singh, J.; Anbalagan, A.; et al. Sub-optimal neutralisation

272 of omicron (B. 1.1. 529) variant by antibodies induced by vaccine alone or SARS-CoV-2
273 Infection plus vaccine (hybrid immunity) post 6-months. *EBioMedicine*. **2022**, 78,
274 103938. <https://doi.org/10.1016/j.ebiom.2022.103938>.

275 18. Takheaw, N.; Liwsrisakun, C.; Chaiwong, W.; Laopajon, W.; Pata, S.; Inchai, J.;
276 Duangjit, P.; Pothirat, C.; Bumroongkit, C.; Deesomchok, A.; et al. Correlation analysis
277 of anti-SARS-CoV-2 RBD IgG and neutralizing antibody against SARS-CoV-2 Omicron
278 variants after vaccination. *Diagnostics*. 2022 12, 1315.
279 <https://doi.org/10.3390/diagnostics12061315>.

280 19. Iketani, S.; Liu, L.; Guo, Y.; Liu, L.; Chan, J. F.; Huang, Y.; Wang, M.; Luo, Y.; Yu, J.;
281 Chu, H.; et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
282 *Nature*. **2022**, 604, 553-6. <https://doi.org/10.1038/s41586-022-04594-4>.

283
284
285
286
287
288
289
290
291
292
293

294 **Figure and Table**

295 **Table 1.** Anti-RBD IgG against wild type, sVNT against omicron, FRNT₅₀ titers against BA.1

296 and BA.2 among the booster vaccination groups.

Booster groups	n	anti-RBD IgG	sVNT	FRNT50 titers	FRNT50 titers
		GMT (95%CI)	median (IQR)	BA.1	BA.2
				GMT (95%CI)	GMT (95%CI)
AZ+AZ+AZ					
Pre-boost	20	67.4 (47.1-96.4)	NA	13 (10.4-16.2)	12.5 (10-15.6)
28 d post-boost	20	298.5 (204.2-436.2)	15 (4.8-21.7)	32.2 (20.1-51.6)	45.6 (28.8-72.3)
AZ+AZ+HM					
Pre-boost	20	46.8 (37.1-59)	NA	14.6 (11.6-18.5)	13 (10.4-16.1)
28 d post-boost	20	2160 (1649-2829)	65.7 (32-77)	396.5 (275.4-570.7)	224.5 (156.4-322.2)
90 d post-boost	20	901.2 (657-1236)	38 (22.5 -52.1)	119.1 (78.5-180.8)	110.5 (75-163)
AZ+AZ+Mo					
Pre-boost	20	43.6 (31.1-61.3)	NA	16.6 (13.2-21)	11 (9.6-12.6)
28 d post-boost	20	3034 (2418-3806)	67.7 (50.5-80.4)	547.8 (415.2-723)	324.2 (213.6-492.2)
90 d post-boost	20	916 (675 - 1243)	54.4 (35.5-88.9)	141 (89.6-221.6)	122 (71.4-208)


AZ+AZ+PF						
Pre-boost	20	43.3 (31.4-56.7)	NA	10 (10)	15 (11.8-19.1)	
28 d post-boost	20	1876 (1581-2227)	70.3 (56.9 -78)	166.3 (114-243.3)	247.7 (179.2-342.4)	
90 d post-boost	20	556 (460-673)	32.5 (17.9-53.8)	78.1(47.5-128.2)	73.8 (56.1-97.2)	
SV+AZ+AZ						
Pre-boost	10	146.5 (77.6-276.3)	11.48 (0.3-18.9)	12.8 (8.8-18.5)	24.4 (16.8-35.4)	
28 d post-boost	20	315.8 (233.5-427)	11.4 (2.6-23.8)	40.3 (27.3-59.6)	59.3 (39.7-88.5)	
SV+AZ+Mo						
Pre-boost	10	98 (66.2-145)	3.58 (1.0-6.6)	11 (8.9-13.5)	12 (9.1-15.7)	
28 d post-boost	20	2930 (2156-3983)	79.7 (61.1-82.4)	271.6 (173-427)	235 (144-385.4)	
SV+AZ+PF						
Pre-boost	10	135.4 (67.7-270.8)	8.1 (4.4-17.3)	17.3 (8.7-34.1)	28.3 (14.8-53.8)	
28 d post-boost	20	3049 (2322-4005)	58.4 (33.1-78.5)	171 (120-243.3)	130.7 (78.9-216.8)	

297 *SV=CoronaVac (Sinovac, China), AZ=AZD1222 (AstraZeneca, Oxford, UK), PF=BNT162b2*

298 *(Pfizer-BioNTech), Mo=full dose mRNA-1273 (100 µg) (Moderna), HM=half dose mRNA-1273*

299 *(50 µg).*

300



301

302 **Figure 1.** Prediction of the level of anti-RBD IgG tested against the ancestral strain and the
 303 percentage of blocking between RBD and ACE-2 interaction against omicron based on the
 304 FRNT₅₀ assay against SARS-CoV-2 omicron BA.1 and BA.2 variants using non-linear
 305 regression analysis. Sera samples (n=310) from individuals with booster vaccination were tested
 306 with anti-RBD IgG, sVNT against omicron and FRNT₅₀ against omicron BA.1 and BA.2.
 307 Predicted anti-RBD IgG (Panel A) and sVNT (Panel B) levels were based on the FRNT₅₀ against
 308 BA.1. Predicted anti-RBD IgG (Panel C) and sVNT (Panel D) levels were based on the FRNT₅₀
 309 against BA.2. The Y axis represents log₁₀ scale of anti-RBD IgG (BAU/mL). The x axis

310 represents the \log_{10} of FRNT₅₀ titers. Dotted lines indicate 1.3 (FRNT₅₀ titer =20) and 1.6
311 (FRNT₅₀ titer =40). The arrows indicate the predicted level of anti-RBD IgG and percentage of
312 inhibition from sVNT. Colored circles indicate the vaccine regimens for primary vaccine series+
313 booster vaccine. The r-square was calculated according to the non-linear equation using STATA
314 v.17.0 software. SV=CoronaVac (Sinovac, China), AZ=AZD1222 (AstraZeneca, Oxford, UK),
315 PF=BNT162b2 (Pfizer-BioNTech), Mo=full dose mRNA-1273 (100 μ g) (Moderna), HM=half
316 dose mRNA-1273 (50 μ g).

317